Immunocore: Strong KIMMTRAK Execution, Robust Late-Stage Pipeline, and Cash-Funded Catalysts Support Buy Rating and $100 Target

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Immunocore Holdings today and set a price target of $100.00.

Patrick Trucchio has given his Buy rating due to a combination of factors including strong execution of KIMMTRAK and a clearly defined late-stage pipeline. He highlights that KIMMTRAK continues to post solid double-digit revenue growth, extended treatment duration, and high penetration in key geographies, cementing its status as the standard first-line therapy for metastatic uveal melanoma, with meaningful additional upside as new markets open and durability data mature.

Moreover, he underscores that the Phase 3 TEBE-AM study is progressing on schedule toward a pivotal overall survival readout around 2026, while the PRAME program and broader TCR platform offer multiple shots on goal across oncology, HIV, and autoimmune disease. With a substantial cash position, ongoing KIMMTRAK cash flows, and several potentially value-creating clinical catalysts expected over the next 12–18 months, Trucchio sees Immunocore as well-positioned for further growth, supporting his Buy rating and $100 price target.

According to TipRanks, Trucchio is a 5-star analyst with an average return of 26.1% and a 49.29% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as COMPASS Pathways, Atai Beckley N.V., and Arrowhead Pharmaceuticals.

In another report released on February 26, Goldman Sachs also maintained a Buy rating on the stock with a $72.00 price target.